Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

Bellicum Pharmaceuticals (BLCM) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 24 quarters since 2015. Compare with BLCM stock chart to see long term trends.

BLCM stock compared to

BLCM Income Statement

Revenue, Net:500000
Revenue Per Share:0.09
Research & Development Expense:8706000
Total Operating Expenses:12142000
Operating Income:-13012000
Net Income:18783000
Earnings Per Share, Basic:6.3
Shares Outstanding, Basic Avg:5760159

BLCM Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:243000
Net Cash from Operations:-13375000
Net Cash from Financing Activities:-4247000
Property, Plant & Equipment Purchases:-182000
Net Cash from Investing Activities:-22000
Net Change in Cash & Equivalents:-17630000

BLCM Balance Sheet

Cash and Cash Equivalents:36996000
Total Current Assets:39443000
Property, Plant & Equipment, Net:189000
Total Assets:40584000
Accounts Payable:891000
Current Portion of Long-Term Debt:0
Total Short-Term Liabilities:24701000
Long Term Debt, Non-Current Portion:0
Total Liabilities:25045000

Major Holders (from 13F filings)

Investment Type
Value (x$1000)
increase or decrease
Vanguard Group Inc
174,003 sh
-2,353 sh
Renaissance Technologies LLC
159,571 sh
-25,500 sh
Blackrock Inc.
102,563 sh
-1,181 sh
Bridgeway Capital Management Inc
28,900 sh
-280 sh
Morgan Stanley
3,093 sh
2,138 sh
Bank Of America Corp /De/
681 sh
-319 sh
Alyeska Investment Group, L.P.
Call options for 0 sh
-200,000 sh
Wolverine Trading, LLC
Call options for 0 sh
-18,700 sh
Panagora Asset Management Inc
0 sh
-285 sh
Proequities, Inc.
0 sh

Data imported from Bellicum Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.